Successful valve-in-valve transcatheter intervention to treat severe stenosis of a 38-year-old tricuspid bioprosthesis.

A 60-year-old man presented with breathlessness. Nearly four decades previously, he had required three operations for Staphylococcus aureus infective endocarditis of the tricuspid valve and had received a bioprosthetic valve. He had critical tricuspid bioprosthesis stenosis which was treated successfully by valve-in-valve transcatheter tricuspid valve replacement using a balloon-expandable transcatheter heart valve.

Percutaneous Transcatheter Valve-in-Valve Pulmonary and Tricuspid Replacement in Carcinoid Heart Disease.

Surgical valve replacement is the most effective treatment for carcinoid heart disease; however, reoperation for prosthetic valve failure is burdened by high risk. We report the first described percutaneous transcatheter pulmonary and tricuspid valve-in-valve replacement for bioprosthesis degeneration for any reason in a patient with carcinoid heart disease. ().

Improving growth of infants with congenital heart disease using a consensus-based nutritional pathway.

Objective: Infants with congenital heart disease (CHD) often experience growth failure prior to surgery, which is associated with increased paediatric-intensive-care unit length of stay (PICU-LOS) and post-operative complications. This study assessed the impact of a pre-operative, consensus-based nutritional pathway (including support from a multi-disciplinary team) on growth and clinical outcome.

Design: Single-centre prospective pilot study.